Pharmaceutical Industry Articles & Reports - Page 40

An analysis of the core technologies and design philosophies of Wolfram Alpha (symbolic AI) and ChatGPT (generative AI), detailing their key differences. Updated for GPT-5.2, Wolfram Language 14.3, and the transition from plugins to Custom GPTs.

A comprehensive guide to pharmaceutical KPIs for quality, compliance, and operational excellence. Covers metrics for R&D, clinical trials, manufacturing, supply chain, and pharmacovigilance, updated with 2025-2026 regulatory developments including FDA QMM, ICH E6(R3), and ISO 9001:2026.

An educational profile of ZUSDURI, a mitomycin hydrogel for intravesical chemoablation of low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). Updated with 2026 J-code reimbursement, UGN-103 UTOPIA trial results, and commercial launch data.

This article explains how pill identifier software improves patient safety by accurately identifying medication using physical traits, AI-powered image recognition, and deep learning models achieving over 96% accuracy, preventing costly medical errors.

An analysis of the Medicare program in 2025, detailing the structure and the significant policy impacts of the One Big Beautiful Bill Act (P.L. 119-21).

Examine 2025 trends for Contract Sales Organizations in pharma. This analysis compares top providers and strategies for HCP engagement and outsourcing.

Examines the evolution of eCTD systems from specialized publishers for regulatory submissions to enterprise platforms that serve as a unified drug lifecycle archive, including the impact of eCTD v4.0, AI-powered RIM tools, and IDMP compliance.

This article explains how AI tools can validate regulatory dossiers, catch technical errors before submission, and minimize rework for emerging biotech companies. Updated with 2025-2026 developments including FDA's ELSA AI assistant, eCTD v4.0 validation updates, McKinsey benchmarks, and the latest Gemini 2.5 vs GPT-5 comparisons.

Updated for 2026, this article examines the unique financial challenges facing regional hospitals — including 46% operating at negative margins — and details the accounting practices, software solutions, and AI-driven automation essential for maintaining stability and compliance.

An overview of San Francisco Bay Area neuroscience firms, updated February 2026. Examines companies in neurotechnology, BCIs, and neuropharmacology, with latest clinical trial results, FDA developments, and funding milestones.

A comprehensive overview of AI in pharmacovigilance (updated Feb 2026), covering agentic AI, GenAI-driven case processing, signal detection, CIOMS WG XIV framework, FDA/EMA joint principles, EU AI Act implications, and the latest industry platforms.

An overview of market access analytics covering its definition, scope, and role in helping pharmaceutical firms navigate complex payer reimbursement models. Updated for 2026 with IRA drug price negotiation impacts, agentic AI platforms, EU HTA harmonisation, and digital therapeutics reimbursement advances.

Learn to design, secure, and manage a HIPAA-compliant API. Updated for 2026 with the proposed Security Rule overhaul, mandatory encryption and MFA requirements, and current enforcement trends.

Learn how WORM (Write Once, Read Many) storage ensures data immutability and integrity for electronic records in the highly regulated biotechnology industry. Updated for 2026 with the latest on EU GMP Annex 11 revisions, SEC 17a-4 audit-trail alternatives, cloud WORM advances, and ransomware defense strategies.

Examine the GPT-5 model family's technical capabilities, ChatGPT Health and ChatGPT for Healthcare launches, applications in life sciences and medicine, and the ethical and regulatory considerations for AI in healthcare. Updated February 2026.

An educational guide to executing compliant pharmaceutical remarketing. Explores platform policies on Google, Meta, LinkedIn, and Reddit, plus data privacy. Updated for 2025-2026 with Meta's health-data restrictions, FDA enforcement escalation, Google policy changes, and HIPAA tracking updates.

Examines the key scientific journals and trade publications in the pharma and biotech industries, covering peer-review, access models, and target audience.

An overview of AI applications in the pharmaceutical sector, from generative AI to ML. Explains key IT management challenges like data, compliance, and security.

Updated 2026 survey of global online degrees and certificates in AI for pharmaceutical science. Compare programs by level, curriculum, cost, and duration – including new offerings from UCSF, Yale, and LIU.

An overview of OpenAI's open-weight GPT-OSS models. Examine their technical specifications, benchmark performance, gpt-oss-safeguard safety models, and applications for reasoning in healthcare.

Examines RegTech adoption challenges for emerging biotechs, focusing on cost, scalability, and AI-driven compliance. Covers flexible licensing, usage-based pricing, deferred-value models, and the latest platform innovations from Veeva Vault Basics and beyond.

Examines how AI accelerates the pharmaceutical drug pipeline, reducing time to market. Updated for 2026 with the latest clinical milestones, FDA guidance, and industry developments including Insilico Medicine's Phase IIa results and the Recursion-Exscientia merger.

An explanation of active learning principles and their adaptation for Large Language Models (LLMs) using human-in-the-loop (HITL) feedback for model alignment, including DPO, GRPO, and RLVR.

An overview of the pharmaceutical industry's history, from 19th-century origins to the current global market size, sales figures, and regional distribution.